Capital Research Global Investors Bridge Bio Pharma, Inc. Transaction History
Capital Research Global Investors
- $443 Billion
- Q2 2024
A detailed history of Capital Research Global Investors transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Capital Research Global Investors holds 2,212,085 shares of BBIO stock, worth $55.2 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,212,085
Previous 2,212,085
-0.0%
Holding current value
$55.2 Million
Previous $68.4 Million
18.08%
% of portfolio
0.01%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding BBIO
# of Institutions
292Shares Held
175MCall Options Held
8.66MPut Options Held
2.76M-
Kohlberg Kravis Roberts & Co. L.P. New York, NY31.1MShares$775 Million45.4% of portfolio
-
Viking Global Investors LP25.1MShares$627 Million2.53% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.1MShares$351 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$310 Million0.01% of portfolio
-
Aisling Capital Management LP New York, NY6.07MShares$151 Million67.33% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $3.7B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...